Therefore, adiponectin replacement therapy in humans may suggest potential versatile therapeutic targets in the treatment of obesity, insulin resistance/type 2 diabetes, and atherosclerosis. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.